Advanced in Febrile Neutropenia

Dr. Nancy M. Hardy

Oncology | Transplant Surgery
University Of Maryland Oncology Associates PA
22 S Green St, 
Baltimore, MD 
Accepting New Patients
Offers Telehealth
Advanced in Febrile Neutropenia
University Of Maryland Oncology Associates PA
22 S Green St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nancy Hardy is an Oncologist and a Transplant Surgeon in Baltimore, Maryland. Dr. Hardy is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hardy is currently accepting new patients.

Her clinical research consists of co-authoring 48 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Transplant Surgery
Licenses
Internal Medicine in NC
Hospital Affiliations
University Of Maryland Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UNIVERSITY OF MARYLAND ONCOLOGY ASSOCIATES PA
22 S Green St, Baltimore, MD 21201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: December 09, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: August 06, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 2
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Other, Biological
Study Drug: AB-205
Study Phase: Phase 3
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CD24Fc, Methotrexate, Tacrolimus
Study Phase: Phase 3
A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: December 16, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: September 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

48 Total Publications

CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma.
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma.
Journal: Haematologica
Published: August 01, 2025
Similar Doctors
Maria R. Baer
Distinguished in Febrile Neutropenia
Dr. Maria R. Baer
Hematology Oncology | Hematology | Oncology
Distinguished in Febrile Neutropenia
Dr. Maria R. Baer
Hematology Oncology | Hematology | Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (0.1 miles away)
410-328-1230
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients

Maria Baer is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Baer is rated as an Elite provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Splenectomy. Dr. Baer is currently accepting new patients.

Distinguished in Febrile Neutropenia
Dr. Vu H. Duong
Hematology Oncology | Hospital Medicine | Hematology
Distinguished in Febrile Neutropenia
Dr. Vu H. Duong
Hematology Oncology | Hospital Medicine | Hematology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (0.1 miles away)
410-328-1230
Languages Spoken:
English
See accepted insurances

Vu Duong is a Hematologist Oncology specialist and a Hospital Medicine provider in Baltimore, Maryland. Dr. Duong is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Myringotomy.

Distinguished in Febrile Neutropenia
Dr. Chanh T. Huynh
Hematology Oncology | Hematology | Oncology
Distinguished in Febrile Neutropenia
Dr. Chanh T. Huynh
Hematology Oncology | Hematology | Oncology

Cancer Care Associates Of York, Inc.

25 Monument Rd, Suite 294, 
York, PA 
 (44.3 miles away)
717-741-9229
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chanh Huynh is a Hematologist Oncology specialist and a Hematologist in York, Pennsylvania. Dr. Huynh is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hardy's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile